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Activation of protein kinase C (PKC) can result from
stimulation of the receptor-G protein-phospholipase C
(PLCb) pathway. In turn, phosphorylation of PLCb by
PKC may play a role in the regulation of receptor-medi-
ated phosphatidylinositide (PI) turnover and intracellu-
lar Ca21 release. Activation of endogenous PKC by phor-
bol 12-myristate 13-acetate inhibited both Gaq-coupled
(oxytocin and M1 muscarinic) and Gai-coupled (formyl-
Met-Leu-Phe) receptor-stimulated PI turnover by 50–
100% in PHM1, HeLa, COSM6, and RBL-2H3 cells ex-
pressing PLCb3. Activation of conventional PKCs with
thymeleatoxin similarly inhibited oxytocin or formyl-
Met-Leu-Phe receptor-stimulated PI turnover. The PKC
inhibitory effect was also observed when PLCb3 was
stimulated directly by Gaq or Gbg in overexpression
assays. PKC phosphorylated PLCb3 at the same predom-
inant site in vivo and in vitro. Peptide sequencing of in
vitro phosphorylated recombinant PLCb3 and site-di-
rected mutagenesis identified Ser1105 as the predomi-
nant phosphorylation site. Ser1105 is also phosphoryl-
ated by protein kinase A (PKA; Yue, C., Dodge, K. L.,
Weber, G., and Sanborn, B. M. (1998) J. Biol. Chem. 273,
18023–18027). Similar to PKA, the inhibition by PKC of
Gaq-stimulated PLCb3 activity was completely abol-
ished by mutation of Ser1105 to Ala. In contrast, mutation
of Ser1105 or Ser26, another putative phosphorylation
target, to Ala had no effect on inhibition of Gbg-stimu-
lated PLCb3 activity by PKC or PKA. These data indicate
that PKC and PKA act similarly in that they inhibit
Gaq-stimulated PLCb3 as a result of phosphorylation of
Ser1105. Moreover, PKC and PKA both inhibit Gbg-stim-
ulated activity by mechanisms that do not involve
Ser1105.
Stimulation of seven transmembrane receptors coupled to
the Gaq or Gai subunits of heterotrimeric G proteins results in
activation of PLCb1 isoforms that hydrolyze phosphatidylinosi-
tol 4,5-bisphosphate to generate the second messengers inositol
1,4,5-trisphosphate (IP3) and diacylglycerol (1, 2). IP3 binds to
a receptor in endoplasmic reticulum and releases intracellular
calcium from its stores. Diacylglycerol, alone or in conjunction
with elevated intracellular calcium, activates PKC and ini-
tiates additional cellular responses (3). Currently, four iso-
forms of mammalian PLCb have been identified and charac-
terized (4–10). Significantly, PLCb3 is ubiquitously expressed
and activated by all known PLCb activators (Gaq, Gbg, and
calcium) (2). Regulation of PLCb3 may be of great importance
in many cellular processes (11–15). Insufficient expression of
PLCb3 has been correlated with increased sensitivity to tumor
formation (15, 16), whereas overexpression of PLCb3 seems to
suppress tumor growth (17). PLCb3 knockout mice exhibit al-
tered response to m-opioids (11) or early embryonic lethality
(18).
Phosphorylation appears to play an important role in regu-
lating the activity of PLCb isoforms. Phosphorylation of PLCb3
or PLCb2 by PKA inhibits their activity and establishes a
mechanism for cross-talk between Gaq- or Gai-coupled and
Gas-coupled receptors (12, 19). The inhibition of G protein-
coupled receptor-mediated PI turnover or intracellular calcium
release by protein kinase C has been reported (20–25). Protein
kinase C is comprised of three subfamilies, the conventional (a,
b1, b2, and g), novel (d, e, h, m, and u), and atypical (z and l)
PKCs (3). The conventional and novel PKCs are activated sub-
sequent to the stimulation of Gaq- or Gai-coupled receptors (3,
26). The inhibition of PI turnover by PKC may present a feed-
back for determining the frequency and amplitude of signals
being transmitted.
The mechanisms by which PKC inhibits agonist-stimulated
PI turnover have not been well defined. PKC can phosphorylate
certain G protein-coupled receptors (platelet-activating factor
receptor, C5A receptor) and thereby inhibit PI turnover or
intracellular calcium release (reviewed in Ref. 27). PKC also
appears to inhibit agonist-stimulated PI turnover at a post-
receptor level (25, 28). Although phosphorylation of PLCb1 and
PLCb2 by PKC has been reported (23, 24, 29, 30), the physio-
logical relevance of these observations has not been demon-
strated. PLCbt, a turkey PLCb isoform with highest homology
to PLCb2, is phosphorylated by conventional PKCs, and its
catalytic activity is inhibited (29). PLCb3 is not phosphorylated
by PKCa in vitro (23). Nonetheless, a correlation between
PLCb3 phosphorylation and PKC inhibition of receptor-initi-
ated PI turnover has been reported (21, 31).
To determine the importance of PLCb3 phosphorylation by
PKC, we have identified the phosphorylation site on PLCb3 and
investigated which PKC subfamily can catalyze the phospho-
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rylation. We report the identification of Ser1105 as the predom-
inant PKC phosphorylation site, the involvement of conven-
tional PKCs in this phosphorylation, and the convergence of
PKC and PKA on phosphorylation and inhibition of PLCb3 by
Gaq. Furthermore, we find that Gbg-stimulated PLCb3 activity
is inhibited by both PKC and PKA by mechanisms that do not
involve Ser1105 phosphorylation.
EXPERIMENTAL PROCEDURES
Materials—Thymeleatoxin (Tx), Go¨ 6976, PKC catalytic fragment,
PKCb1, and PKCg were obtained from Calbiochem. H-89 was pur-
chased from Seikagaku America, Inc. (Rockville MD). PMA, CPT-cAMP
(8-[4-chlorophenythiol]-cAMP), and other chemicals were purchased
from Sigma. Lys C was obtained from Wako Bioproducts (Richmond,
VA). Modified sequence grade trypsin, GeneEditor site-directed mu-
tagenesis kit, and the gel drying film were purchased from Promega
(Madison, WI). LipofectAMINE, Dulbecco’s modified Eagle’s medium
(DMEM), phosphate-free DMEM, and all other cell culture reagents
were obtained from Life Technologies, Inc. [3H]Inositol (22 Ci/mmol)
was obtained from American Radiolabeled Chemical Co. (St. Louis,
MO), [32P]orthophosphate (5 mCi/ml) and g-[32P]ATP (3000 Ci/mmol)
were from Amersham Pharmacia Biotech. The RBL-2H3 cell line stably
expressing fMLP receptor and fMLP were provided by Dr. D. Haviland,
University of Texas, Houston. The plasmid encoding PKA catalytic
subunit was provided by Dr. G. S. McKnight, Washington University
(Seattle, WA).
Cloning, Site-directed Mutagenesis, and Protein Purification—
PLCb3, Gaq, Gb1, and Gg2 plasmids were constructed as described
elsewhere (12, 32). Site-directed mutation of Ser26 to Ala was achieved
with the mutagenic primer (59-CGGCGCGGGGCTAAGTTCATCAAAT-
GG-39) identically as described for the Ser1105 3 Ala mutation (12)
using GeneEditor. All plasmid sequences were confirmed by DNA se-
quencing. Construction of baculovirus containing PLCb3 Ser
11053 Ala-
(His)6 and purification of the recombinant protein from Sf9 cells were
carried out as described for PLCb3 (His)6 (12).
In Vivo and in Vitro 32P Labeling and Isolation of PLCb3—For in vivo
phosphorylation, COSM6 cells seeded in 6-well plates were transfected
with PLCb3(His)6 plasmid and metabolically labeled with [
32P] ortho-
phosphate (0.10 mCi) in 0.5 ml of phosphate-free DMEM for 90 min.
After PMA (1 mM) treatment for 30 min, cells were lysed in 500 ml of
M-PER lysis buffer (Pierce) containing a mixture of protease and phos-
phatase inhibitors (21) and centrifuged at 15,000 3 g for 5 min at 4 °C.
Phosphorylated PLCb3(His)6 was isolated with nickel-nitrilotriacetic
acid resin, separated on a 7.5% SDS-polyacrylamide gel, stained with
Coomassie Blue, and analyzed by autoradiography.
In vitro phosphorylation by PKC was carried out according to proto-
cols provided by the vendor. Briefly, 0.8 mM purified recombinant
PLCb3(His)6 or PLCb3Ser
1105 3 Ala(His)6 was incubated with purified
constitutively active PKC fragment (0.04 mM) in the presence of 2.5 mCi
of [g-32P]ATP and 100 mM ATP in a total volume of 10 ml of PKC buffer
(50 mM MES, pH 6.5, 1.25 mM EGTA, 12.5 mM MgCl2) for the times
specified at 30 °C. Equal amounts of PLCb3(His)6 were also incubated
for 40 min with purified PKCb1 or PKCg (20 ng) in a total volume of 10
ml of reaction buffer (20 mM HEPES, pH 7.4, 100 mM CaCl2, 10 mM
MgCl2, 100 mg/ml phosphatidylserine, 20 mg/ml diacylglycerol, 0.03%
Triton X-100). Reactions were terminated by adding 10 ml of 23 SDS
sample buffer and boiling for 5 min. Proteins were separated by 7.5%
SDS-polyacrylamide gel electrophoresis and stained with Coomassie
Blue. The phosphorylated bands were localized by autoradiography.
The stoichiometry of PLCb3 phosphorylation by PKC was determined at
100 min by filter binding assay as described elsewhere (12).
Phosphoamino Acid Analysis, Peptide Mapping, and Sequencing—
For two-dimensional tryptic peptide mapping and phosphoamino acid
analysis, 32P-labeled PLCb3 from in vivo or in vitro phosphorylation
reactions was separated by SDS-polyacrylamide gel electrophoresis.
The gel was stained with Coomassie Blue, dried between two layers of
drying membranes, and exposed to Biomax-MS x-ray film (Eastman
Kodak Co.). PLCb3 bands were cut out and rehydrated in 50 mM
ammonium bicarbonate, pH 8 (buffer A), overnight. After peeling off the
drying membrane, each gel slice was boiled for 5 min in 100 ml of buffer
A containing 5 mM dithiothreitol. The tube was cooled to room temper-
ature, 50 ml of 100 mM iodoacetic acid was added, and the tube was
incubated for 30 min in the dark at room temperature. The gel slice was
washed again in buffer A and ground with a disposable pestle. The
residual Coomassie Blue dye was removed by rinsing the gel slurry with
FIG. 1. Prior treatment with PMA or Tx inhibits oxytocin (OT), carbachol, or fMLP-stimulated total IP production in PHM1–41 (A),
HeLa (B), COSM6 (C) or RBL-2H3 (D) cells, respectively. HeLa and COSM6 cells were transfected with (M1R) or without (Vector) a plasmid
expressing M1 receptor and were stimulated with 15 mM carbachol. Where indicated, PBS was used as control reagent. Data are presented as the
means 6 S.E. (n 5 3) of 1 of 2–4 similar experiments and were analyzed by analysis of variance and Duncan’s test. Groups with different letters
are different from each other at p , 0.05.
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50 ml of 50% acetonitrile in buffer A. The tube was centrifuged at
15,000 3 g for 5 min, and the supernatant was discarded. The pellet
was resuspended in 50 ml of acetonitrile and incubated for 5 min. The
tube was centrifuged again, and the pellet was dried in a SpeedVac for
10 min after removal of supernatant. The pellet was resuspended in 75
ml of buffer A, and 2 mg of trypsin was added. The tube was incubated
at 37 °C for 5 h before the addition of another 2 mg of trypsin, and the
total incubation time was between 18 and 24 h. The liquid containing
the digested peptides was recovered and further prepared for two-
dimensional peptide mapping with a Hunter thin layer electrophoresis
system (C.B.S. Scientific Co., Del Mar, CA) according to the protocol
provided by the manufacturer. External markers for each dimension
were included in each thin layer plate to facilitate the comparison
between samples. For phosphoamino acid analysis, about 100 cpm of
total tryptic peptides mixture was used. Peptide sequencing using 32P-
labeled PLCb3(His)6 (150 pmol) recombinant protein purified from Sf9
cells was carried out as described elsewhere (12).
Cell Culture, Transfection, and PI Turnover—HeLa, COSM6, and
RBL-2H3 cells were cultured as described for PHM1-41 cells (33). HeLa
and COSM6 cells (1.8 3 105/well) were seeded in 6-well plates and
transfected 16–24 h later as described (34) with M1 receptor (1 mg), Gaq
(0.5 mg), Gb1 (0.375 mg), Gg2 (0.375 mg), and PLCb3 (0.25 mg) as
indicated. Empty rcCMV vector was added to bring the total amount of
plasmid DNA to 1.25 mg per well. For effects of endogenous PKC on
agonist-stimulated PI turnover, near confluent PHM1 and RBL-2H3
cells (12-well plates) and COSM6 and HeLa cells (6-well plates) were
treated with 1 mM PMA or 100 ng/ml thymeleatoxin for 30 min in PBS1
(phosphate-buffered saline (PBS) plus 1.2 mM Ca21, 1.0 mM Mg21, and
1.0 mM glucose) containing 10 mM LiCl prior to stimulation by agonists
(100 nM oxytocin, 15 mM carbachol, or 100 nM fMLP) for 30 min. Where
indicated, H-89 (10 mM) or Go¨ 6976 (8 mM) were added to PHM1-41 cells.
After 15 min, PMA or CPT-cAMP were added, followed by oxytocin 15
min later. For direct stimulation of PLCb3 by Gaq or Gb1g2, transfected
COSM6 cells were first treated with 1 mM PMA for 30 min in PBS1
followed by addition of 20 mM LiCl for 30 min. Cells were lysed, and
total IPs were determined as described (19).
RESULTS
PKC Inhibits Oxytocin, M1 Muscarinic, and fMLP Receptor-
initiated PI Turnover—The effect of activation of endogenous
PKC on predominantly Gaq-coupled oxytocin receptor-initiated
PI turnover (35) was studied in PHM1-41 cells, a human myo-
metrial smooth muscle cell line (33). Stimulation of PHM1 cells
with 100 nM oxytocin significantly increased the production of
total IPs. Pretreating cells with 1 mM PMA completely inhibited
this increase (Fig. 1A). The PMA effect was not specific to the
oxytocin receptor or to PHM1-41 cells. A similar inhibitory
effect of PMA was also evident with Gaq-coupled M1 musca-
rinic receptor transfected into HeLa (Fig. 1B) or COSM6 (Fig.
1C) cells. In addition, PMA also significantly inhibited Gai-
coupled fMLP receptor-initiated PI turnover (36) in RBL-2H3
cells (Fig. 1D) in which the only PLCb form expressed is PLCb3
(21). This occurred under conditions where the fMLP receptor
has been shown not to be phosphorylated by PKC (37). These
observations, together with those previously reported (21, 31),
establish that the PKC inhibitory effect on G protein-coupled
receptor-initiated PI turnover is a general mechanism and that
the PKC effect can occur at a post-receptor level.
To investigate the potential role of specific PKCs in this
process, the effect of Tx, a specific activator of conventional
PKCs (38), was compared with PMA, which activates both
conventional and novel PKCs (38), in PHM1-41 and RBL-2H3
cell lines. In both cases, Tx was as effective as PMA in inhib-
iting oxytocin or fMLP-stimulated PI turnover at the concen-
tration tested (Fig. 1, A and D). In addition, Go¨ 6976, an
inhibitor of conventional PKC (39), was able to reverse the
PMA inhibitory effect by ;50% at a concentration of 4 mM (data
not shown). These data provide evidence that conventional
PKCs are capable of inhibiting Gaq- or Gai-coupled receptor-
initiated PI turnover.
PKC Inhibits the Direct Stimulation of PLCb3 by Gaq and
Gbg—Because PLCb3 is present in all four cell lines mentioned
above and can be phosphorylated by PKC, at least in RBL-2H3
cells (21), it is highly possible that PKC inhibits PI turnover by
decreasing PLCb3 activity. If so, PKC should inhibit the direct
stimulation of PLCb3 by Gaq or Gbg. COSM6 cells transfected
with both PLCb3 and Gaq plasmids exhibited a marked in-
crease in total [3H]IPs compared with transfection with either
plasmid alone (Fig. 2A). Consistent with the prediction, pre-
treating cells with PMA nearly abolished Gaq-stimulated
PLCb3 activity. Tx elicited a similar inhibitory effect on Gaq-
stimulated PLCb3 activity (data not shown). Cotransfection of
Gb1g2 and PLCb3 into COSM6 cells also resulted in marked
increase in PI turnover. This increase was significantly re-
duced by PMA (Fig. 2B), but the reduction was not of the
magnitude observed for Gaq-stimulated PLCb3. Thus PKC in-
hibition of PI turnover occurs at a post-receptor level, and this
effect may require the phosphorylation of PLCb3.
Phosphorylation of PLCb3 by PKC in Vivo and in Vitro—
PLCb3 overexpressed in COSM6 cells exhibited significant
32P
incorporation under basal conditions. Nonetheless, PMA in-
duced a substantial increase in 32P incorporation into PLCb3
(Fig. 3A). The phosphorylation of PLCb3 by PKC was investi-
gated further in vitro. Purified recombinant PLCb3 was incu-
bated with catalytically active PKC fragments (a rat brain
mixture of multiple PKC isoforms, including a, b, and g) in the
presence of [g-32P]ATP. As shown in Fig. 3B, PLCb3 was phos-
FIG. 3. A, in vivo 32P labeling of PLCb3(His)6 isolated from COSM6
cells transfected with PLCb3(His)6 plasmid and pretreated with (PMA)
or without (control) PMA. B, time-dependent phosphorylation of
PLCb3(His)6 by PKC in vitro. Reactions were terminated at the times
indicated in minutes. Coomassie Blue staining of the respective gels is
shown below the autoradiographs. C, autoradiography of PLCb3(His)6
after incubation without (2) or with (1) purified PKCb1 and PKCg in
vitro.
FIG. 2. PMA inhibits Gaq-stimu-
lated PLCb3 (A) and Gbg-stimulated
PLCb3 (B) activity in COSM6 cells
transfected with plasmids expressing
Gaq, Gbg, and PLCb3. Data are pre-
sented as the means 6 S.E. (n 5 3) of 1 of
3 similar experiments and were analyzed
by analysis of variance and Duncan’s test.
Groups with different letters are different
from each other at p , 0.05.
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phorylated in a time-dependent manner. A stoichiometry of 0.4
mol of phosphate/PLCb3 was achieved after incubation with
PKC for 100 min under these conditions. In similar experi-
ments, no phosphorylation was seen in the absence of PKC
(data not shown). Purified PKCb1 or PKCg also phosphorylated
PLCb3 in vitro, whereas no phosphorylation of PLCb3 was
observed in the absence of kinase (Fig. 3C).
Ser1105 Is the Predominant Phosphorylation Site for
PKC—As shown by two-dimensional phosphopeptide mapping
of in vivo 32P-labeled PLCb3, trypsin digestion yielded multiple
phosphopeptides in the basal state (Fig. 4A). PMA specifically
induced phosphorylation on one predominant site (Fig. 4B,
indicated by the arrow). Minor sites increased by PMA were
also present (indicated by arrowhead). We cannot exclude the
contribution of incomplete digestion by trypsin to this pattern.
In vitro, PKC phosphorylated PLCb3 on one predominant
site (Fig. 4C, arrow). The migration of this peptide relative to
the standards was identical to those observed in digests after in
vivo phosphorylation. The phosphorylation occurred exclu-
sively on serine residues (Fig. 4D). We utilized in vitro phos-
phorylated recombinant PLCb3(His)6 to identify the PKC phos-
phorylation sites. After isolation by SDS-polyacrylamide gel
electrophoresis, 32P-labeled PLCb3 was digested with Lys C
instead of trypsin to achieve more complete cleavage and fewer
peptides (12). The digestion mixture was separated by reverse-
phase high pressure liquid chromatography, and fractions were
recovered and counted. Fig. 5A shows the 32P distribution
among these fractions. About 8% of 32P was found in the follow-
through (fraction 21 to 24) and appeared to be free 32P as
judged by phosphopeptide mapping (data not shown). Nearly
60% of the total 32P was recovered in fraction 12. This fraction
was subjected to peptide sequencing. Although two peptides
were identified in this fraction, nearly 90% of the total 32P was
found in the fourth cycle (Fig. 5B). This clearly identified
Ser1105 and not Ser1107 in the peptide Arg-His-Asn-Ser1105-Ile-
Ser-Glu-Ala-Lys as the amino acid phosphorylated. Further-
more, mutation of Ser1105 significantly diminished PLCb3
phosphorylation by PKC in vitro (Fig. 5C). This strongly argues
that Ser1105 is the predominant site for PKC. Residual weak
phosphorylation associated with Ser1105 3 Ala mutant PLCb3
could indicate the presence of other minor sites. Interestingly,
Ser1105, unique to PLCb3 among the PLCb isoforms, is prefer-
entially phosphorylated by PKA as well (12).
FIG. 5. A, 32P distribution among fractions collected after reverse-phase high pressure liquid chromatography separation of Lys C-digested
PLCb3(His)6 labeled with
32P in vitro. Fraction 12 has ;60% of the total 32P. B, sequence of peptides in fraction 12 and associated 32P. The serine
residue with more than 90% of total 32P loaded onto the sequencing membrane is denoted by *. filter represents 32P left on the sequencing
membrane after 10 cycles. C, in vitro phosphorylation by PKC (30 min at 30 °C) of recombinant wild type (WT) or Ser1105 3 Ala mutant (S/A)
PLCb3(His)6 purified from Sf9 cells. The Coomassie Blue staining (Coomassie) and autoradiography (autorad) of the same gel are shown.
FIG. 6. Mutation of Ser1105 to Ala (S/A) reversed the inhibition
by PKC of Gaq-stimulated PLCb3 in COSM6 cells transfected
with plasmids expressing Gaq and PLCb3 plasmids. Data are
presented as the means 6 S.E. (n 5 3) of 1 of 3 similar experiments and
were analyzed by analysis of variance and Duncan’s test. Groups with
different letters are different from each other at p , 0.05.
FIG. 4. Two-dimensional tryptic peptide mapping of PLCb3(His)6
32P-labeled in vivo (A and B) or in vitro (C). Two markers were
applied on each TLC plate as migration controls for each dimension. The black markers on the top of each panel indicate the position of one such
marker; others outside of the displayed region were also used in lining up the plates. “O” depicts the sample origin. The predominant
PKC-stimulated phosphorylation site is indicated by the arrows (B and C) and the minor sites by the arrowheads. Longer exposure of C revealed
some minor sites as well. D, two-dimensional phosphoamino acid analysis of PLCb3(His)6 phosphorylated by PKC in vitro. The dotted circles
indicate the migration positions of phosphoserine (PS), phosphothreonine (PT), and phosphotyrosine (PY) standards.
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Functional Analysis of Phosphorylation of PLCb3 by PKC
Versus PKA—We have previously shown that phosphorylation
by PKA of Ser1105 is required for inhibition of Gaq-stimulated
PLCb3 activity by PKA. The finding that PKC also phospho-
rylates Ser1105 suggested that the same mechanism was uti-
lized by PKC. To test this hypothesis, the Ser11053 Ala mutant
PLCb3 was cotransfected with Gaq into COSM6 cells, and the
effect of PMA was evaluated. As shown before (12), the Ser1105
3 Ala mutant PLCb3 was as effective as the wild type enzyme
in coupling to Gaq (Fig. 6). Importantly, PMA inhibited Gaq-
stimulated wild type PLCb3 activity but had no effect on Gaq-
stimulated Ser11053 Ala PLCb3 activity. These data unequiv-
ocally identify phosphorylation of Ser1105 by PKC as
responsible for PKC inhibition of Gaq-stimulated PLCb3
activity.
We also investigated the effect of mutating Ser1105 on PKC
inhibition of Gbg-stimulated PLCb3 activity. The Ser
11053 Ala
mutant PLCb3 was as effective as wild type PLCb3 in coupling
to Gb1g2 (Fig. 7A). However in contrast to Gaq-stimulated
PLCb3 activity, PKC inhibited Gb1g2-stimulated Ser
11053 Ala
mutant PLCb3 activity to the similar degree as it did the wild
type PLCb3. Thus Ser
1105 is not absolutely required for PKC
inhibition of Gb1g2-stimulated PLCb3 activity. The N-terminal
region of PLCb3 appears to contribute to its interaction with
Gbg (40). We had identified Ser26 in the peptide Arg-Arg-Gly-
Ser-Lys as a potential phosphorylation site in this region. How-
ever, there was no effect of mutating Ser26 to Ala on PKC
inhibition of Gbg-stimulated PLCb3 activity (Fig. 7A).
In the face of the inability of mutation of Ser1105 and Ser26 to
reverse the effect of PKC on Gbg-stimulated PLCb3 activity, we
examined the effect of mutation of these residues on PKA-
mediated inhibition as well. As seen in Fig. 7B, PKA inhibited
Gbg-stimulated PLCb3 activity. Mutation of Ser
1105 or Ser26
also had no effect on inhibition by PKA of Gbg-stimulated
PLCb3 activity.
Inhibition of Oxytocin-stimulated Total IP Production in
PHM1-41 Cells by PKC or PKA Represents Independent Path-
ways—Phosphoryation of Ser1105 by PKC or PKA suppressed
Gaq-stimulated PLCb3 activity. This fact raised the interesting
possibility that PKC activation might lead to PKA activation,
resulting in indirect phosphorylation of PLCb3 at the PKA site
or vice versa. We addressed this possibility in PHM1-41 cells.
As shown in Fig. 8, H-89, a specific PKA inhibitor, reversed the
inhibition by cAMP but did not affect the inhibition by PMA of
oxytocin-stimulated PI turnover. Similarly, Go¨ 6976, a specific
PKC inhibitor, significantly diminished the inhibitory effect of
PMA but not of cAMP on oxytocin-stimulated PI turnover.
These data indicate that PKC and PKA exert their inhibitory
effects independent of each other.
DISCUSSION
We have presented evidence that PKC inhibits Gaq-coupled
(oxytocin and M1 muscarinic) and Gai-coupled receptor (fMLP)
receptor-initiated PI turnover in four different cell lines ex-
pressing PLCb3. The response to endogenous PKC activation
by PMA differs in order of magnitude between cell lines and the
state of the receptor (endogenous or transfected). This varia-
tion may reflect differences in relative membrane permeability
of PMA and the localization and abundance of the PKC iso-
forms responsible or the relative contribution of Gaq-coupling
to PLCb3 to PI turnover. We have also demonstrated in co-
transfection assays that the PKC inhibitory effect occurred at
the G protein-PLCb3 level, and we have provided direct evi-
dence to support the hypothesis that phosphorylation of PLCb3
FIG. 7. Inhibition of Gbg-stimulated Ser11053 Ala and Ser263
Ala mutant PLCb3 activity by PKC (A) or PKA (B) in COSM6
cells transfected with plasmids expressing Gbg, wild type (WT),
Ser1105 3 Ala or Ser26 3 Ala mutant PLCb3. A, data are presented
as the means 6 S.E. ( n 5 3) of 1 of 3 similar experiments and were
analyzed by analysis of variance and Duncan’s test. Groups with dif-
ferent letters are different from each other at p , 0.05. B, plasmid
encoding the PKA catalytic subunit was cotransfected into COSM6 cells
(filled bars), and its expression was induced with 60 mM ZnSO4 for 24 h
after transfection. Data represent the mean of duplicate determinations
(range denoted by the error bars) in 1 of 2 similar experiments.
FIG. 8. Inhibition of oxytocin-stimulated total IP production
in PHM1–41 cells by PKC or PKA represents independent path-
ways. Data are presented as the means 6 S.E. (n 5 3) from 1 of 2
similar experiments and were analyzed by analysis of variance and
Duncan’s test. Groups with different letters are different from each
other at p , 0.05.
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is involved in the PKC inhibitory effect on Gaq-coupled
activation.
The use of in vitro phosphorylated PLCb3 for identifying the
PKC phosphorylation site is supported by the demonstration
that a similar site was phosphorylated by PKC in vivo and in
vitro. PKC phosphorylates predominantly one residue, Ser1105,
that is also phosphorylated by PKA (12). The marked reduction
of in vitro phosphorylation of the Ser11053 Ala PLCb3 mutant
further corroborates this finding. However, the remaining
weak phosphorylation associated with this mutant indicates
that PKC may phosphorylate other minor sites as well.
Mutation of Ser1105 to Ala reversed completely the inhibition
of Gaq-stimulated PLCb3 activity by PKC. This provides con-
clusive evidence for the direct inhibition of PLCb3 by PKC, a
response identical to that seen previously for PKA (12). We also
demonstrated that the inhibitory effect of PKC occurs in the
absence of PKA inhibition, suggesting that it is not a conse-
quence of indirect PKA activation. The convergence of PKC and
PKA on Ser1105 underscores the importance of Ser1105 in the
regulation of Gaq-stimulated PLCb3 activity in diverse cellular
processes and suggests possible redundancy for the inhibition
of PLCb3 activity by these two kinases. In addition, these data
also argue that the effect of PKC or PKA targets PLCb3 and not
G protein or proteins involved in the production of substrate
phosphatidylinositol 4,5-bisphosphate, as mutation of Ser1105
can completely reverse the inhibition by PKC or PKA of Gaq-
stimulated PLCb3 activity.
In marked contrast, Ser1105 does not appear to be critical for
inhibition of Gbg-stimulated PLCb3 activity by either PKC or
PKA. Ser26 was also not required, although the N-terminal
region of PLCb3 appears to contribute to its interaction with
Gbg (40). At present the mechanism for the inhibition of Gbg-
stimulated PLCb3 activity by PKC or PKA remains unknown.
It is unlikely that Gb1g2 is the direct target for the inhibitory
effects of PKA or PKC as these proteins are not phosphorylated
by PKC or PKA in vitro.2 Identification of PKA or PKC minor
phosphorylation sites may help to solve this question. Alterna-
tively, the mechanism may involve phosphorylation of other
molecules indirectly involved in the coupling (12).
The effects of a conventional PKC-specific activator and an
inhibitor indicate that conventional PKCs are capable of phos-
phorylating PLCb3. This conclusion is supported by in vitro
phosphorylation of PLCb3 by the constitutively active PKC
fragment and by purified PKCb1 and PKCg. The wide distri-
bution of conventional PKCs (26) and PLCb3 (2) in tissues
correlates well with the generality of the PKC inhibitory effect
on receptor-initiated PI turnover.
We conclude that conventional PKCs phosphorylate PLCb3
and inhibit Gaq- and Gbg-stimulated PLCb3 activity. PKC and
PKA act similarly in that they inhibit Gaq-stimulated PLCb3
as a result of phosphorylation of Ser1105. Moreover, PKA and
PKC both inhibit Gbg-stimulated activity by mechanisms that
do not involve Ser1105.
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